GRIM19 ameliorates acute graft-versus-host disease (GVHD) by modulating Th17 and Treg cell balance through down-regulation of STAT3 and NF-AT activation by Min-Jung Park et al.
Park et al. J Transl Med  (2016) 14:206 
DOI 10.1186/s12967-016-0963-0
RESEARCH
GRIM19 ameliorates acute 
graft-versus-host disease (GVHD) 
by modulating Th17 and Treg cell balance 
through down-regulation of STAT3 and NF-AT 
activation
Min‑Jung Park1†, Seung Hoon Lee1†, Sung‑Hee Lee1, Eun‑Kyung Kim1, Eun Jung Lee1, Young‑Mee Moon1 
and Mi‑ La Cho1,2,3*
Abstract 
Background: T helper (Th) 17 cells are a subset of T helper cells that express interleukin (IL)‑17 and initiate the 
inflammatory response in autoimmune diseases. Regulatory T cells (Tregs) are a subpopulation of T cells that produce 
forkhead box P3 (FOXP3) and inhibit the immune response. Graft versus host disease (GVHD) is a complication of allo‑
geneic tissue transplantation, and Th17 cells and their proinflammatory activity play a central role in the pathogenesis 
of GVHD. Gene associated with retinoid‑interferon‑induced mortality (GRIM) 19, originally identified as a nuclear pro‑
tein, is expressed ubiquitously in various human tissues and regulate signal transducer and activator of transcription 
(STAT)3 activity.
Methods: Splenoytes and bone marrow cells were transplanted into mice with GVHD. The alloresponse of T cells and 
GVHD clinical score was measured. Realtime‑polymerase chain reaction (realtime‑PCR) was used to examine mRNA 
level. Flow cytometry and enzyme linked immunosorbent assay (ELISA) was used to evaluate protein expression.
Results: A GRIM19 transgenic cell transplant inhibited Th17 cell differentiation, alloreactive T cell responses, and 
STAT3 expression in mice with GVHD. On the other hand, the differentiation of Tregs and STAT5 production were 
enhanced by GRIM19. Overall, the severity of GVHD was decreased in mice that had received GRIM19 transgenic bone 
marrow and spleen transplants. Transplantation from GRIM19‑overexpressing cells downregulated the expression 
of nuclear factor of activated T cells (NFATc1) but promoted the expression of regulator of calcineurin (RCAN)3 while 
downregulating NFAT‑dependent cytokine gene expression. This complex mechanism underlies the therapeutic 
effect of GRIM19.
Conclusions: We observed that GRIM19 can reduce Th17 cell differentiation and alloreactive T cell responses in vitro 
and in vivo. Additionally, GRIM19 suppressed the severity of GVHD by modulating STAT3 activity and controlling Th17 
and Treg cell differentiation. These results suggest that GRIM19 attenuates acute GVHD through the inhibition of the 
excessive inflammatory response mediated by T cell activation.
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Background
Graft-versus-host disease (GVHD) is a condition induced 
by the release of excessive inflammatory cytokines. 
Donor-derived naive CD4+ T cells activated by alloanti-
gens play an important role in the pathogenesis of GVHD. 
It has been demonstrated that GVHD is an immune 
inflammatory disease. It is a complication of bone marrow 
transplants. When donor-derived T cells differentiate into 
T helper (Th) cell subsets, they can produce unique sets of 
transcription factors and cytokines that can damage host 
tissues [1–3]. It has been suggested that Th1 cell allore-
sponses can induce transplant rejection. The progression 
of GVHD can be explained mainly by a Th1 response [4, 
5]. However, Th17 cells and regulatory T cells (Tregs) have 
also been implicated in GVHD. It is well documented that 
Th17 cells can contribute to the severity of GVHD with 
the Th17/Treg ratio being higher in patients with GVHD 
[6]. Moreover, Th17 cell numbers are increased while Treg 
cell numbers are reduced in peripheral blood mononu-
clear cells of GVHD patients [7]. Recently, signal trans-
ducer and activator of transcription 3 (STAT3) has been 
described as an important regulator of Th17/Treg cells. 
Inhibition of STAT3 activation can reduce Th17 cell num-
bers but increase Treg numbers, thus attenuating inflam-
matory disorders [8, 9].
Gene associated with Retinoid-Interferon-induced 
Mortality (GRIM)19 is a 16-kDa protein primarily iden-
tified as a nuclear protein expressing constitutively in 
several human tissues. GRIM19 was first recognized as 
a factor involved in apoptosis [10]. GRIM19 also plays a 
role in inflammation because the expression of GRIM19 
is diminished in inflamed mucosa of inflammatory bowel 
disease patients [11]. In addition, GRIM19 can interact 
with STAT3, a cytoplasmic transcription factor in Th17 
cells. It has been suggested that GRIM19 can inhibit 
the transcriptional activity of STAT3 [12]. In addition, 
GRIM19 is involved in mitochondrial respiration and 
tumorigenesis via STAT3-responsive gene expression. 
Overexpression of GRIM19 has therapeutic proper-
ties against cancer by inhibiting STAT3-mediated signal 
transduction, while the absence of GRIM19 abrogates 
mitochondrial respiratory chain function and acceler-
ates tumor development by enhancing the expression 
of STAT3-responsive genes [13–15]. Recently, GRIM19 
has been suggested as a significant factor involved in 
Th17/Treg balance and STAT3 activation in inflamma-
tory disease. Overexpression of GRIM19 can inhibit 
inflammation and improve collagen-induced arthritis by 
controlling the differentiation of Th17 cells and Tregs 
[16]. Here, we hypothesized that GRIM19 could reduce 
inflammatory response and regulate Th17/Treg balance 
in GVHD. To determine whether GRIM19 could attenu-
ate GVHD, first we evaluated the role of GRIM19 in the 
alloreactive T cell response both in  vivo and in  vitro. 
We then determined the therapeutic function and anti-
inflammatory activity of GRIM19 in  vivo in a mouse 
model of GVHD. To understand how GRIM19 could 
decrease the inflammatory response, we analyzed its 
effect on Th17/Treg balance controlled by the STAT3 
pathway in a GVHD mouse model.
Methods
Mice
C57BL/6 (B6, H-2  kb) and BALB/c (B/c, H-2kd) mice 
at 8–10  weeks of age were purchased from OrientBio 
(Sungnam, Korea). To generate GRIM19 transgenic 
mice, a pcDNA3.1+ (Invitrogen) vector was constructed 
containing CMV promoter. The GRIM19 fragment was 
synthesized by GenScript Corporation (NJ, USA), with 
codon optimization for expression in mammalian cells. 
The origin of open reading frame is mice. GRIM19 trans-
genic mice overexpresssing Grim19 were generated on 
a C57BL/6 background and maintained in facilities at 
(Macrogen Inc., Seoul, Korea) by microinjection of a 
transgene. GRIM19 transgenic mice founder transgenic 
mice were mated to C57BL/6 J mice. The presence of the 
transgene in the founders was confirmed by PCR using 
genomic DNA extracted from the tails of mice. GRIM19 
transgenic mice were generated as previously described 
[16]. Mice were maintained under specific pathogen-free 
conditions in an animal facility with humidity of 55 ± 5 % 
and temperature of 22  ±  1  °C under 12/12-h of light/
dark. The air in the facility was passed through a HEPA 
filter system to exclude bacteria and viruses. Animals 
were allowed ad  libitum access to mouse chow and tap 
water. The protocols used in this study were approved by 
the Animal Care and Use Committee of the Catholic Uni-
versity of Korea.
BMT model and histopathological scoring
Recipients B/c mice were intravenously injected with 
5  ×  106 donor bone marrow cells after lethal irradia-
tion with 700 cGy. Irradiated recipients received a single 
intravenous injection of WT or GRIM19 Tg splenotyces 
(1 × 107 cells) through a lateral tail vein. Survival of mice 
after BMT was monitored daily. The extent of clinical 
GVHD was assessed weekly using a scoring system based 
on the following five clinical parameters: weight loss, 
posture, activity, fur texture, and skin integrity. Mice were 
euthanized on day 14 after BMT prior to blinded histo-
pathology evaluation for GVHD target tissues such as 
skin, liver, small intestine, and large intestine [17]. Organs 
were harvested, cryo-embedded, and subsequently sec-
tioned. Thsee sections were fixed in 10 % (v/v) buffered 
formalin and stained with hematoxylin and eosin (H&E) 
for histological examination.
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Alloreactive T cell responses in vitro
Splenocytes derived from B/c mice were used as “stimu-
lator” cells in the context of allorecognition. Cells from 
B6 WT or GRIM19 Tg mice were used as “responder” 
cells. Splenocytes were harvested in ACK lysis buffer 
(0.15 M NH4Cl, 10 mM KHCO3, and 0.1 mM EDTA; pH 
7.2–7.4), washed, and resuspended in complete culture 
medium (RPMI 1640 supplemented with 10 % [v/v] heat-
inactivated fetal calf serum). Aliquots of 2 × 105 CD4+ T 
cells (responders) were cultured with 2 × 105 irradiated 
(2500  cGy) APCs in 96-well plates containing 200  µl/
well of complete medium. Cells were incubated at 37 °C 
with a humidified 5  % (v/v) CO2/air atmosphere. Cells 
were pulsed with 1 µCi of tritiated thymidine (3[H]-TdR; 
NEN Life Science Products Inc., Boston, MA, USA) 18 h 
before harvesting and counted with an automated har-
vester (PHD Cell Harvester (Cambridge Technology, Inc., 
Cambridge, MA, USA). Results were expressed as mean 
cpm values of triplicate samples ± SD.
Real‑time polymerase chain reaction (PCR)
Total RNA was extracted using the TRI reagent (Molecu-
lar Research Center, Inc. Cincinnati, OH, USA) according 
to the manufacturer’s instructions. Complementary DNA 
was synthesized using SuperScript reverse transcription 
system (Takara). A Light-Cycler 2.0 instrument (software 
version 4.0; Roche Diagnostics) was used for PCR amplifi-
cation. All reactions were performed using the LightCycler 
with FastStart DNA Master SYBR Green I mix (Takara) 
following the manufacturer’s instructions. The following 
primers were used to amplify mouse genes: Il-17, 5′-CCT-
CAA-AGC-TCA-GCG-TGT-CC-3′ (sense) and 5′-GAG-
CTC-ACT-TTT-GCG-CCA-AG-3′ (antisense); Foxp3, 
5′-GGC-CCT-TCT-CCA-GGA-CAG-A-3′ (sense) and 
5′-GCT-GAT-CAT-GGC-TGG-GTT-GT-3′ (antisense); 
Ifn-r, 5′-GAA AAT CCT GCA GAG CCA GA-3′ (sense) 
and 5′-TGA GCT CAT TGA ATG CTT GG-3′ (antisense); 
Il-4, 5′-TCA ACC CCC AGC TAG TTG TC-3′ (sense) and 
5′-TGT TCT TCG TTG CTG TGA GG-3′ (antisense); 
Grim19, 5′-TCG-CCC-TTA-ATG-GTC-AGT-TC-3′ 
(sense) and 5′-CGA-GGA-GGA-TTT-TGA-GTG-TG-3′ 
(antisense); and regulator of calcineurin 3 (Rcan3), 
5′-AGC–AGC-TGT-GTC-AGA-TGG-TG-3′ (sense) and 
5-’CTG-AGC-AGT-CCC-CTG-TAA-GC-3′ (antisense). 
All transcriptional levels were normalized to that of 
β-actin.
Flow cytometry
Mononuclear cells were immunostained with various 
combinations of fluorescent antibodies against CD4, 
CD25, FOXP3, IFN-γ, IL-4, IL-6, and IL-17 (eBioscience, 
San Diego, CA, USA). Prior to intracellular staining, cells 
were restimulated with phorbol myristate acetate (PMA; 
25  ng/mL) and ionomycin (250  ng/mL) in the presence 
of GolgiSTOP (BD Biosciences) for 4  h. Intracellular 
staining was conducted using a kit (eBioscience) follow-
ing the manufacturer’s protocol. Flow cytometry analysis 
was performed on a FACSCalibur flow cytometer (BD 
Biosciences).
Elisa
The protein levels of IL-1β, IL-6, IL-17 and TNF-α in 
serum or culture supernatants were measured using 
sandwich ELISA (Duoset; R&D Systems, Lille, France). 
Serum levels of IgG and IgG1 antibodies were measured 
using a commercially available ELISA kit (Bethyl Labora-
tories, Montgomery, TX, USA).
Staining for confocal microscopy analysis
Spleen tissue was obtained 14  days after BMT, snap-
frozen in liquid nitrogen, and stored at −80  °C. Tissue 
cryosections (7  μm thick) were fixed with acetone and 
stained with FITC-, PE-, PerCP-Cy5.5-, or APC- con-
jugated monoclonal antibodies against mouse CD4, 
pSTAT3 (Tyr 705, Ser 727), pSTAT5, NFATc1, RCAN3, 
PD-1, CTLA-4, IFN-γ, IL-4, IL-17, and FOXP3 (eBiosci-
ence). After incubation overnight at 4 °C, stained sections 
were visualized by confocal microscopy (LSM 510 Meta; 
Zeiss, Göttingen, Germany). Immunohistochemistry was 
performed using Vectastain ABC kit (Vector Laborato-
ries, Burlingame, CA, USA). Tissues were incubated with 
primary mouse anti-RCAN3 antibody overnight at 4 °C. 
Primary antibodies were detected using a biotinylated 
secondary antibody followed by incubation with strepta-
vidin-peroxidase complex for 1  h. DAB chromogen was 
added (Dako, Carpinteria, CA, USA) to obtain the final 
colored product. Positive cells were counted and results 
were expressed as mean ± SD.
Immunohistochemistry
Immunohistochemistry was performed using the Vec-
tastain ABC kit as mentioned earlier. Tissues were incu-
bated with primary anti-c-Jun and anti-c-Fos antibodies 
overnight at 4  °C. The primary antibody was detected 
with a biotinylated secondary antibody followed by incu-
bation with a streptavidin-peroxidase complex for 1  h. 
DAB chromogen was added to obtain colored product.
Murine T cell isolation and differentiation
To purify splenic CD4+ T cells, splenocytes were incu-
bated with anti-CD4-coated magnetic beads. CD4+ T 
cells were isolated using magnetic-activated cell sort-
ing (MACS) separation columns (Miltenyi Biotec). 
Cells were cultured in the presence of plate-bound anti-
CD3 and soluble anti-CD28 (each at a concentration of 
1  µg/mL; both from BD PharMingen), anti-interferon γ 
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(anti-IFN-γ), and anti-IL-4 (each at a concentration of 
5 µg/mL) for 3 days. Th17 cell differentiation was induced 
by treatment with IL-6 (20  ng/mL) and transforming 
growth factor β (TGF-β; 2 ng/mL). The cells were treated 
by STAT5 inhibitor (Santa Cruz) to reduce STAT5 
expression.
Transfection
To generate GRIM19 overexpression vector, Grim19 frag-
ment was synthesized by TOPgene Technologies (Que-
bec, Canada) with codon optimization for expression 
in mammalian cells. It was subcloned into the BamH1 
and Xho1 sites of pcDNA3.1(+) (Invitrogen). Mock and 
GRIM19 vector constructs were transfected using Amaxa 
4D-Nucleofector X unit (Lonza, Switzerland) according 
to the manufacturer’s recommendations with the pro-
gram DN-100 and P3 primary cell solution.
RNA interference
To knock down the expression of GRIM19, CD4+ T cells 
were purified and nucleoporated with siRNA specific for 
Grim19 or scrambled siRNA (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA), using an Amaxa Nucleoporator 
system. Briefly, 5–10  ×  106 CD4+ T cells were resus-
pended in 100 μL nucleofector solution and transfected 
with 100 nM siRNA using the U-014 Amaxa nucleofector 
program (Lonza, Switzerland). After transfection, cells 
were incubated at 37 °C for 6 h and stimulated with anti-
CD3/CD28-coated magnetic beads under Th17-polariz-
ing conditions for 48 h.
Statistical analysis
Statistical analysis was performed with nonparametric 
Mann–Whitney U test using IBM SPSS Statistics 20 for 
Windows (IBM Corp., Armonk, NY, USA). p < 0.05 was 
considered as statistically significant. Data were pre-
sented as mean ± standard deviation (SD).
Results
GRIM19 inhibits alloreactive T cell response both in vitro 
and in vivo
As GVHD is induced by the activation of host-reac-
tive donor T cells, persistence of alloreactive T cells is 
required for the development of GVHD [18]. Therefore, 
we first investigated whether GRIM19 could reduce allo-
reactive T cell response. In a mixed lymphocyte reaction 
(MLR), CD4+ T cells from B6 WT or GRIM19 Tg mice 
were cultured with allogeneic APCs. The alloreactive T 
cell response observed through the number of GRIM19 
CD4+ T cells was decreased significantly (p < 0.05) com-
pared to that with WT CD4+ T cells (Fig.  1a). In addi-
tion, IL-17 expression by GRIM19 CD4+ T cells was 
significantly (p < 0.05) reduced compared to that by WT 
CD4+ T cells (Fig. 1b). To verify the function of GRIM19 
in inhibiting alloreactive T cell response, bone marrow 
(BM) and spleen (SP) from GRIM19 Tg mice were trans-
planted into recipient mice. BM and BM  +  SP groups 
had significantly (p < 0.05) higher survival rate than that 
of controls. The GVHD clinical score was also improved 
after the transplantation of BM or BM  +  SP from 
GRIM19 Tg mice, including no weight loss (Fig. 1c).
GRIM19 has therapeutic activity of improving acute GVHD 
severity and inflammation
Acute GVHD primarily affects skin, gastrointestinal 
tract, and liver [19–22]. Therefore, histopathology anal-
ysis was performed for intestinal, skin, and liver tissues 
to determine whether GRIM19 could reduce the sever-
ity of GVHD. The pathology score of the BM or BM + SP 
group was significantly (p < 0.05) lower than that of the 
control (Fig. 2a, b). Since GVHD is mediated by immune 
inflammation, we also measured IgG and proinflamma-
tory cytokines concentrations. Both IgG and IgG1 levels 
were significantly (p < 0.05) reduced by the transplanta-
tion of BM or BM + SP from GRIM19 Tg mice. TNF-α, 
IL-1β, and IL-6 production in both GRIM19 Tg BM and 
BM  +  SP groups were lower than that in the control 
(Fig. 2c, d). These results showed that transplantation of 
BM or BM + SP derived from GRIM19 Tg mice attenu-
ated the severity of GVHD.
GRIM19 regulates T helper cell response
GVHD is characterized by the differentiation of T cells 
present in the graft [1]. Excessive production of cytokines 
such as IL-1β, IL-6, IL-17, and IFN-γ by differentiated T 
cells can lead to inflammatory response and cause damage 
to several host tissues in GVHD [23]. In order to exam-
ine whether GRIM19 could regulate Th cell response, we 
analyzed Th cell subsets in the spleen. The expression of 
IL-1β, IL-6, IL-17, and IFN-γ were decreased in splenic 
CD4+ T cells from GRIM19 tg BM and BM + SP groups. 
The transcriptional levels of Il-1β, Il-6, Il-17, and Ifn-γ in 
splenocytes from GRIM19 tg BM and BM +  SP groups 
were also significantly (p < 0.05) lower than those in the 
controls. On the other hand, the protein level of IL-4 
was increased in splenic CD4+ T cells from GRIM19 tg 
BM and BM  +  SP groups. The transcriptional levels of 
Il-4 in splenocytes from GRIM19 tg BM and BM  +  SP 
groups were also significantly (p < 0.05) higher than those 
in the controls (Fig.  3a, b). Confocal microscopy analy-
sis revealed that the number of CD4+ T cells producing 
IL-17 and IFN-γ was significantly (p  <  0.05) decreased. 
However, the number of CD4+ T cells expressing IL-4 
in splenocytes from the GRIM19 tg BM and BM  +  SP 
groups was increased significantly (p < 0.05) compared to 
that of the controls (Fig. 3c).
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STAT3 is an important transcription factor for Th17 
differentiation [24]. Therefore, we evaluated the expres-
sion of STAT3. The number of cells expressing acti-
vated form of STAT3, p-STAT3 Tyr705, and Ser727 was 
reduced significantly (p  <  0.05) among splenic CD4+ T 
cells from GRIM19 tg BM and BM + SP groups (Fig. 3d).
GRIM19 induces Tregs by promoting STAT5 expression
Cytotoxic T-lymphocyte antigen (CTLA)-4 and pro-
grammed death (PD)-1 receptor are expressed on the 
surface of activated T cells [25]. Tregs, a subset of T cells, 
have immunosuppressive functions. They also express 
CTLA-4 and PD-1. Their differentiation is regulated by 
STAT5 [24, 26]. Reduced number of Tregs is known to 
be a key factor in GVHD pathophysiology [27]. In addi-
tion, Treg/Th17 ratio is a specific indicator of human 
GVHD [28]. Therefore, we measured the expression lev-
els of CTLA-4, PD-1, FOXP3, and STAT5 in the spleen 
and lymph nodes of mice with GVHD. FOXP3 expres-
sion was found to be increased in the spleen and lymph 
nodes of GRIM19 tg BM and BM + SP groups (Fig. 4a). 
The number of Treg cells expressing CTLA-4, PD-1, and 
pSTAT5 was also increased in the spleens of GRIM19 
tg BM and BM + SP groups (Fig. 4b, c). Next, we deter-
mined whether GRIM19 expression might play a role 
in Treg differentiation. To test whether GRIM19 could 
induce FOXP3 expression, we transfected murine CD4+ 
T cells with a GRIM19 overexpression vector. The tran-
scriptional levels of Grim19 and Foxp3 were significantly 
(p  <  0.05) higher in GRIM19-overexpressing CD4+ T 
cells compared to those in mock vector group (Fig. 4d). 
We also investigated the interaction between Grim19 and 
Foxp3. The transcriptional level of Foxp3 gene in CD4+ 
T cells from GRIM19 Tg mice was higher than that from 
WT CD4+ T cells. Moreover, the transcriptional level 
of Foxp3 in GRIM19 Tg CD4+ T cells was significantly 
(p < 0.05) reduced by STAT5 inhibitor (Fig. 4e).
IL‑17 is inhibited by reduced STAT3‑NFATc1 expression
Since NFATc1 and STAT3 cooperatively exacerbate 
inflammation [29] while RCAN3 inhibits the gene 
expression of NFAT-dependent cytokines [30], we meas-
ured the protein level of NFATc1 in the spleen of GVHD 
mice. NFATc1 protein level was decreased in the spleens 
of GRIM19 tg BM and BM +  SP groups while the pro-
tein level of RCAN3 was increased (Fig. 5a, b). The tran-
scriptional level of Rcan3 mRNA was also increased 
significantly (p < 0.05) in the spleens of GRIM19 tg BM 
and BM +  SP groups compared to that in the controls 
(Fig.  5c). Next, we transfected murine CD4+ T cells 
Fig. 1 GRIM 19 blocks alloreactive T cell responses both in vitro and in vivo. a In the mixed lymphocyte reaction (MLR) assay, a total of 105 RBC‑
lysed B6 or GRIM19 splenic T cells (responders) were incubated with 105 irradiated RBC‑lysed Balb/c splenic APCs (allogeneic [allo] stimulators) or 
B6 splenic APCs (syngeneic [syn] stimulators) for 4 days. T cell proliferation was measured through 3[H]‑TdR incorporation. b IL‑17 levels were deter‑
mined in supernatants using ELISA. Data represent the mean ± SD of triplicate experiments. Data are representative of at least three independent 
experiments. c Recipients (B/c mice) were intravenously injected with 5 × 106 donor (WT or GRIM19 Tg) bone marrow cells and 1 × 107 splenocytes 
after lethal irradiation. Data are representatives of at least three independent experiments. GVHD clinical manifestations after allogeneic BMT were 
scored for weight loss, posture, activity, fur texture, and skin integrity. The combined data from two independent experiments (n = 20 per group). 
**p < 0.01 compared to GVHD control
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with a GRIM19 overexpression vector to verify whether 
GRIM19 could regulate the transcriptional level of Il-17 
and Rcan3. Our results revealed that the transcriptional 
level of Il-17 was reduced significantly (p  <  0.05) while 
the transcriptional level of Rcan3 was increased signifi-
cantly (p  <  0.05) in GRIM19-overexpressing cells com-
pared to that in mock vector-transfected cells (Fig.  5d). 
To confirm that GRIM19 could regulate the expression 
of Il-17 and Rcan3, we evaluated the mRNA expression 
levels of Il-17 and Rcan3 in murine CD4+ T cells treated 
with Grim19 siRNA. Treatment with Grim19 siRNA sig-
nificantly (p  <  0.05) reduced the transcriptional level of 
Rcan3 gene. However, the transcriptional level of Il-17 
was significantly (p < 0.05) increased after Grim19 siRNA 
treatment (Fig. 5e). We also studied the effect of GRIM19 
on the production of IL-17. Based on ELISA, IL-17 pro-
duction was decreased (p < 0.05) significantly by GRIM19 
overexpression. On the other hand, Grim19 siRNA and 
STAT5 inhibitor significantly (p < 0.05) upregulated the 
protein level of IL-17 (Fig. 5f ).
Fig. 2 GRIM19 attenuates acute GVHD severity and inflammation. a Recipients (B/c mice) were intravenously injected with 5 × 106 donor (WT 
or GRIM19 Tg) bone marrow cells and 1 × 107 WT or GRIM19 Tg splenocytes after lethal irradiation. Histopathology results of the skin, liver, small 
intestine, and lung on day 14 after BMT (n = 12 per group) from one of two independent experiments are shown. Sections were stained with H&E 
(original magnification, ×200). b Histopathology score of the skin, liver, small intestine, and lung tissues. Results are expressed as mean ± SD from 
six mice. *p < 0.05, **p < 0.01. c Twelve days after BMT, serum levels of IgG in the three groups were measured by ELISA. Data are expressed as 
means ± SD from eight mice. *p < 0.05, **p < 0.01, ***p < 0.001. d Serum levels of IFN‑γ, IL‑17, and IL‑10 in three groups were measured by ELISA. 
Data are expressed as means ± SD from eight mice. *p < 0.05, **p < 0.01, ***p < 0.001
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Discussion
The role of GRIM19 in apoptosis has been studied exten-
sively [10]. Recently, GRIM19 has also been found to 
be involved in inflammatory diseases and T cell-medi-
ated immune responses. However, little is known about 
the mechanism of GRIM19 activity in GVHD. Here, 
we investigated the therapeutic function of GRIM19 
in GVHD and identified a new mechanism for GVHD 
modulation.
The most remarkable finding of this research was that 
GRIM19 attenuated GVHD via downregulating allore-
active T cell response. To our knowledge, this is the first 
Fig. 3 GRIM19 regulates T helper cell responses. a Recipients (n = 6 B/c mice per group) were intravenously injected with 5 × 106 donor (WT or 
GRIM19 Tg) bone marrow cells and 1 × 107 WT or GRIM19 Tg splenocytes after lethal irradiation. Intracellular cytokines were detected in CD4+ T 
cells. Fourteen days after BMT, splenocytes were isolated and the expression levels of IL‑4, IL‑17, and IFN‑γ were determined by flow cytometry. b 
The mRNA levels of Il‑17, Il‑4, Treg, and Ifn‑γ were analyzed by quantitative PCR. **p < 0.01. c Fourteen days after BMT, splenocytes were isolated and 
stained with anti‑CD4 followed by reacting with anti‑IL‑17, anti‑IL‑4, and anti‑IFN‑γ antibodies. The expression patterns were visualized by confocal 
microscopy. d Expression levels of intracellular signaling molecules p‑STAT3 (Tyr705) and p‑STAT3 (Ser727) in splenic CD4+ T cells were determined 
by confocal microscopy on day 14 after allogeneic BMT. Confocal microscopy images were obtained for each mouse (n = 6 per group) and repre‑
sentative images are shown. Bars represent the mean ± SD from six mice per group. *p < 0.05, **p < 0.01. Data are representative of at least three 
independent experiments
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study that provides evidence suggesting that GRIM19 
could be used as a therapeutic agent to treat GVHD. Pre-
vious reports have demonstrated that alloreactive T cell 
responses contribute to GVHD [18, 31]. In addition, it 
has been suggested that IL-17 can increase the severity 
of GVHD by activating CD4+ T cells [32]. Our results 
indicated that GRIM19 could inhibit alloreactive T cell 
responses and IL-17 production well known to be able 
to reduce GVHD severity, suggesting a novel therapeutic 
strategy to modulate GVHD via GRIM19.
GVHD affects several tissues, including the skin, liver, 
and intestine that are damaged in acute GVHD [19–22]. 
As GVHD is an immune inflammatory disease, IgG 
expression [33, 34] and levels of inflammatory mediators 
such as IL-1β, IL-6, and TNF-α is increased in patients 
with GVHD [35–38]. In this study, transplantation of BM 
and SP from GRIM19 Tg mice was found to be able to 
improve the pathological status. Moreover, the produc-
tion of IgG and proinflammatory cytokines that could 
induce the classical cytokine storm were significantly 
reduced in GRIM19 Tg groups. These results suggest that 
GRIM19 can reduce GVHD severity by inhibiting IgG 
and proinflammatory cytokine productions.
Several subsets of T cells take are involved in the 
pathogenesis of GVHD. Indeed, the production of 
cytokines including IFN-γ by Th1 cells [39, 40] and IL-17 
expression by Th17 cells contributes to GVHD morbid-
ity [32]. By contrast, inhibition of Th17 differentiation 
Fig. 4 GRIM19 regulates Treg/Th17 ratio via inhibiting STAT3 pathway. a Recipients (B/c mice) were intravenously injected with 5 × 106 donor (WT 
or GRIM19 Tg) bone marrow cells and 1 × 107 WT or GRIM19 Tg splenocytes after lethal irradiation. Intracellular immunostaining was performed 
for FOXP3+ Treg (CD4+CD25+) cells in spleen and LN. Data in the left panel are representatives of three independent experiments. Bars show the 
mean ± SD of at least three independent experiments. b Fourteen days after BMT, isolated spleens were analyzed by confocal microscopy for the 
expression of GITR and PD‑1 among CD4+CD25+Foxp3+ regulatory T cells. Bars represent the SD of six mice per group. c The expression of signal 
transducer phosphorylated STAT5 in the spleens was analyzed by confocal microscopy on day 14 after BMT. Data are representatives of three inde‑
pendent experiments. d Splenic CD4+ T cells were sorted from B6 mice and transfected with mock or GRIM19 vector. Mock or GRIM19‑transfected 
T cells were activated by stimulation with anti‑CD3/CD28 for 3 days. Grim19 and Foxp3 mRNA levels were determined by real‑time PCR. Data are 
expressed as mean ± SD of three independent experiments. *p < 0.05, **p < 0.01 vs. mock. e Splenic CD4+ T cell isolated from WT or GRIM19 Tg 
mice were activated by stimulation with anti‑CD3/CD28 for 3 days. A STAT5 inhibitor was added at priming. Foxp3 mRNA level was determined by 
real‑time PCR. Data are expressed as mean ± SD of three independent experiments
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Fig. 5 GRIM19 inhibits IL‑17 by downregulating STAT3‑NFATc1. a Recipients (B/c mice) were intravenously injected with 5 × 106 donor (WT or 
GRIM19 Tg) bone marrow cells and 1 × 107 WT or GRIM19 Tg splenocytes after lethal irradiation. The expression levels of intracellular signaling 
molecules p‑NFATc1 and RCNA3 in the spleen were determined by confocal microscopy on day 14 after allogeneic BMT. All confocal microscopy 
images were obtained for each mouse (n = 6 per group). Representative images are shown. b Immunohistochemical staining for RCAN3 in spleen 
tissue from GVHD mice. Positive immunoreactivity appears as a brown color. It is counterstained with blue or green. Original magnification, ×400. 
c Fourteen days after BMT, Rcan3 mRNA levels in splenocytes were determined by real‑time PCR. d Splenic CD4+ T cells from B6 mice were trans‑
fected with mock or GRIM19 expression vector. Mock or GRIM19‑transfected CD4+ T cells were activated by stimulation with anti‑CD3/CD28 (Th0 
condition) for 3 days. GRIM9, Il‑17, and Rcan3 mRNA levels were determined by real‑time PCR. e Splenic CD4+ T cells from B6 mice were transfected 
with mock or Grim19 siRNA under Th0 conditions. Il‑17 and Rcan3 mRNA levels were determined by real‑time PCR. f Splenic CD4+ T cells from B6 
mice were transfected with GRIM19‑overexpression vector, Grim19 siRNA, or STAT5 inhibitor. IL‑17 levels in supernatants were measured by ELISA. 
Data are expressed as mean ± SD of three independent experiments
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significantly reduced tissue pathology in the liver and 
intestine [41]. Moreover, Th1 and Th17 cells can accel-
erate the development of GVHD [42] whereas Th2 cells 
revealed protective function in GVHD [39], and attenu-
ated the GVHD severity through IL-4-mediated mecha-
nism [43]. Additionally, the immunosuppressive function 
of Tregs plays a pivotal role in the suppression of GVHD 
[27, 44]. Mechanistically, T cell subset differentiation is 
regulated by different transcription factors. Indeed, Th17 
cell differentiation is regulated by STAT3, while Treg dif-
ferentiation is controlled by STAT5 [24, 42]. In patients 
with GVHD, p-STAT3 Tyr 705 is enhanced significantly. 
In addition, Th17 cells are associated with GVHD sever-
ity [45]. Conversely, STAT5 can induce Treg differentia-
tion and limit human T cell alloresponses [46, 47]. Our 
results revealed that GRIM19 could inhibit canonical 
function of STAT3 regulating the expression of proin-
flammatory cytokines. These data indicate that GRIM19 
has therapeutic function for GVHD based on the regu-
lation of Th17/Treg balance through suppressing STAT3 
expression and inducing STAT5 expression.
NFATc1 is a member of the NFAT family of tran-
scription factors involved in T cell activation. Several 
researchers have reported that STAT3 activation can 
increase the expression of NFATc1 and that the interac-
tion between STAT3 and NFATc1 will aggravate inflam-
mation [29, 48]. Moreover, suppression of NFATc1 can 
improve inflammatory diseases [49, 50]. RCAN3 is a cal-
cineurin inhibitor like FK506 and can reduce cytokine 
mRNA levels associated with NFAT [30]. In this study, 
the transplantation of BM and SP from GRIM19 Tg mice 
downregulated the expression of NFATc1 but induced 
the production of RCAN3. GRIM19 overexpression also 
decreased gene expression of Il-17 and the production of 
IL-17 cytokine. However, it increased the mRNA level of 
Rcan3. In addition, the inhibition of GRIM19 and STAT5 
increased the expression level of Il-17 mRNA and IL-17 
protein but reduced the mRNA expression of Rcan3. 
Thus, GRIM19 could decrease inflammation via inhibit-
ing the STAT3-NFATc1 axis.
There are some limitations of this study. First, this 
study had a relatively short-term follow up of GVHD 
in several in vitro assays and in vivo tests that demon-
strated attenuation in GVHD severity. We did not show 
the activity of GRIM19 in GVHD with a long-term fol-
low up. Further study is merited to follow-up the GVHD 
mouse model for longer time to confirm the function 
of GRIM19. Clinical application using Grim19 overex-
pression to suppress T cell activation and inflammation 
is also needed to confirm the translational potential 
of GRIM19 for treating GVHD. Another limitation of 
this study was the measurement of GVL activity. Gen-
erally, inhibition of alloreactive T cells can effectively 
prevent GVHD. However, it usually leads to reduced 
GVL activity which can appear after allogeneic hemat-
opoietic stem cell transplantation. Although knowing 
the mode of action of GRIM19 is important to effec-
tively treat GVHD, the mechanism of RCAN3 is not 
revealed in this study. Further studies are required to 
investigate the translational potential of Grim19 overex-
pressed cells and determine the mechanisms involved in 
RCAN3 action.
Conclusion
Our findings suggest a therapeutic effect of GRIM19. 
It will shed new light on the treatment of GVHD. We 
demonstrate that GRIM19 inhibits the canonical STAT3 
pathway and controls reciprocal regulation Th17/Treg. 
This empirical evidence demonstrates that GRIM19 is a 
promising candidate for treating GVHD.
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